HOME >> MEDICINE >> NEWS
Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., South San Francisco, Calif., which manufactures bevacizumab, provided bevacizumab for the trial under the Cooperative Research and Development Agreement (CRADA) with NCI for the clinical development of bevacizumab.

The Data Monitoring Committee overseeing the trial (known as E4599)* recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of improving overall survival. Researchers found that patients in the study who received bevacizumab in combination with standard chemotherapy (a treatment regimen of paclitaxel and carboplatin) had a median overall survival of 12.5 months compared to patients treated with the standard chemotherapy alone, who had a median survival of 10.2 months. This difference is statistically significant. Detailed results from this trial will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) to be held in Orlando, Fla., on May 13-17, 2005.

"The exciting results of this randomized study reveal, for the first time, an improvement in survival with the addition of a targeted agent to standard chemotherapy in this patient population," said Study Chair Alan B. Sandler, M.D., of the Vanderbilt University Medical Center in Nashville, Tenn.

"This study demonstrates that mechanistic-based interventions such as angiogenesis inhibitors are making important contribution
'"/>

Contact: NCI Press Officers
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
14-Mar-2005


Page: 1 2 3

Related medicine news :

1. Tuberculosis drug combined with virtual reality therapy is effective in treating fear of heights
2. Detrol LA combined with standard treatment for enlarged prostate is twice as effective
3. Nicotine more addictive when combined with other tobacco smoke chemicals, UCI study finds
4. Cognitive behavioral therapy combined with antidepressant effective in treating adolescent OCD
5. Heart disease kills more women annually than all cancers combined
6. Stents combined with clot-busting drugs effective in limiting impact of deadly form of stroke
7. Study shows people with Alzheimers can benefit from exercise combined with caregiver training
8. Wyeth chemists honored for Prevnar first combined pneumococcal vaccine for infants
9. Task force issues caution on combined hormone therapy
10. University of Pittsburgh research shows combined PET/CT finds cancerous lesions standard CT misses
11. Some patients are candidates for combined heart bypass, lung transplant surgeries

Post Your Comments:
(Date:6/30/2015)... ... June 30, 2015 , ... ... partnership with Knockout Zone Miami (KO Zone), a state-of-the-art training ... and CrossFit Coach, Diego de Vera. The partnership will provide KO Zone clients ...
(Date:6/30/2015)... ... June 30, 2015 , ... Due to today’s housing market, many people cannot afford to “down ... have to make adjustments as to how to carry laundry or groceries from one level ... in the basement or first floor of the home, and the bedrooms are located on ...
(Date:6/30/2015)... ... ... The campaign aims to make digestive wellness a more conversational topic, educating ... 70 million Americans face and inspiring readers to be more proactive by providing them ... component of “Digestive Wellness” is distributed within USA Today in Los Angeles, New York, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up to ... Back pain can range from a dull, constant ache (chronic) to a sudden sharp ... epidural steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain & ...
(Date:6/30/2015)... ... 2015 , ... It has become fairly common to purchase fresh broccoli at ... stalks before cooking. Throwing out radish greens, beet leaves and chard stalks is pretty ... just takes a little knowledge and practice to use them. Josie's Organics ...
Breaking Medicine News(10 mins):Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 2Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 3Health News:Butler Mobility Products announce a Solution to Carry Items from One Floor to the Next with a Dumbwaiter 2Health News:Mediaplanet’s “Digestive Wellness” Campaign Urges You To Listen to What Your Stomach Is Telling You and Talk About It 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 3Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 4
(Date:6/30/2015)... -- July 4 th is this weekend, a time we ... people behind it. To help honor our current nation,s heroes, ... Medical Card, a leading provider of free pharmacy ... independence for our disabled military veterans, police, firemen, and EMS ... prescriptions. "Due to USA ...
(Date:6/30/2015)... Minn. , June 30, 2015  EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering  of 40,229,886 units. Each ... of a Series A warrant to purchase one share ... warrant to purchase one share of common stock, at ...
(Date:6/30/2015)... 2015  Marken, the leading clinical trial logistics organization ... has been granted permission by the government to deliver ... product in Korea.  This precedent-setting shipment has allowed several ... continue receiving their clinical trial drugs during the outbreak ... emergency was caused by recent partial closures of medical ...
Breaking Medicine Technology:Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3
Cached News: